Yes, was expecting news today, all my guess, AMRN may be in bed with
street to kill Sept calls by delaying topline to next week, if RRR
is 20+%, results of PE and major SE are clear cut way above SS, no need
looking more data minnings, when in 8% to 12%, AMRN needs more detailed
comments of SE data or more subgroup data in topline PR to convince
street the total efficacy is meaningful to patients and cost/effective
to insurance coverage. ALL is my opinion and no facts to back it up,
but I have to act on my instincts. I can be totally wrong too!!!
Market Data 
Markets 
AI
